Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial

Basit Öğe Kaydı
dc.contributor.authorLena, H.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorHarputluoglu, H.
dc.contributor.authorWauters, E.
dc.contributor.authorRossi, S.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorHelissey, C.
dc.date.accessioned2025-11-16T19:35:06Z
dc.date.issued2025
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15551
dc.identifier.volume20
dc.identifier.wosWOS:001469780300030
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleEvaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu